Cargando…
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
BACKGROUND: Acute osteomyelitis is typically caused by Gram-positive pathogens, commonly antibiotic-resistant Staphylococcus species. Standard antibiotic treatment is challenging due to required multiple daily doses, therapeutic drug monitoring, and parenteral administration for at least 4 weeks. Or...
Autores principales: | Van Hise, Nicholas W., Chundi, Vishnu, Didwania, Vishal, Anderson, Michael, McKinsey, David, Roig, Ingrid, Sharma, Akhilesh, Petrak, Russell M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334313/ https://www.ncbi.nlm.nih.gov/pubmed/32588385 http://dx.doi.org/10.1007/s40801-020-00195-7 |
Ejemplares similares
-
1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019) -
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline
por: Van Hise, Nicholas, et al.
Publicado: (2020) -
838. Oral Vancomycin Prophylaxis Works!
por: Van Hise, Nicholas W, et al.
Publicado: (2019) -
2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019) -
Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
por: Petrak, Russell M., et al.
Publicado: (2021)